John Elsen, MD
Family Medicine · Evergreen Park, ILNPI 1437260940
Payments from drug & device makers
Across 391 payments — averaging $12,845 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.6M
- Bavarian Nordic A/s$2M
- Genentech, Inc.$148K
- Hoffmann-la Roche Limited$135K
- AstraZeneca$66K
- Merck$60K
- plus $32K from 15 others
Across 8 payments — averaging $66.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$530
What the payments were for
- Travel & lodging$98525%
- Food & beverage$2,93975%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 144 | $2,556,515 |
| Bavarian Nordic A/s | 93 | $2,025,201 |
| Genentech, Inc. | 17 | $147,584 |
| Hoffmann-la Roche Limited | 5 | $135,231 |
| AstraZeneca | 24 | $65,669 |
| Merck | 29 | $60,393 |
| AbbVie(2 entities) | 19 | $15,087 |
| GSK | 4 | $13,728 |
| F. Hoffmann-la Roche AG | 4 | $1,832 |
| Novo Nordisk | 19 | $463 |
| Amgen | 9 | $130 |
| Lilly USA, LLC | 5 | $99 |
| Amarin Pharma, Inc. | 4 | $82 |
| Dexcom, Inc. | 2 | $57 |
| Johnson & Johnson | 3 | $55 |
| Exact Sciences | 3 | $53 |
| Astellas Pharma US Inc | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$113
How this compares
$5,022,320 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 109 | $104,068 |
| MounjaroTirzepatide | 40 | $55,037 |
| JardianceEmpagliflozin | 39 | $53,249 |
| JanuviaSitagliptin Phosphate | 34 | $48,093 |
| XareltoRivaroxaban | 24 | $38,120 |
| OzempicSemaglutide | 23 | $32,673 |
| FarxigaDapagliflozin Propanediol | 19 | $30,809 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,588 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $15,932 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,783 |
| Atorvastatin Calcium | 623 | $6,501 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $4,042 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,989 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,936 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 183 | $3,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,556,515 | $104,068109 claims |
| MerckJanuvia, Janumet Xr | $60,393 | $64,02548 claims |
| Lilly USA, LLCMounjaro | $99 | $55,03740 claims |
| Boehringer IngelheimJardiance | $27 | $53,24939 claims |
| Johnson & JohnsonXarelto | $55 | $38,12024 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $13,728 | $35,36151 claims |
| Novo NordiskOzempic | $463 | $32,67323 claims |
| AstraZenecaFarxiga | $65,669 | $30,80919 claims |
| AbbVieSynthroid | $15,087 | $2,25045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Evergreen Park
- George ThomasEvergreen Park$124K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.